Limits...
Macrophage subtype predicts lymph node metastasis in oesophageal adenocarcinoma and promotes cancer cell invasion in vitro

View Article: PubMed Central - PubMed

ABSTRACT

Background:: Currently, there is a lack of ideal biomarkers for predicting nodal status in preoperative stage of oesophageal adenocarcinoma (EAC) to aid optimising therapeutic options. We studied the potential of applying subtype macrophages to predict lymph node metastasis and prognosis in EAC.

Material and methods:: Fifty-three EAC resection specimens were immunostained with CD68, CD40 (M1), and CD163 (M2). Lymphatic vessel density (LVD) was estimated with the staining of D2-40. Subsequently, we tested if M2d macrophage could promote EAC cell migration and invasion.

Results:: In EAC without neoadjuvant treatment, an increase in M2-like macrophage was associated with poor patient survival, independent of the locations of macrophages in tumour. The M2/M1 ratio that represented the balance between M2- and M1-like macrophages was significantly higher in nodal-positive EACs than that in nodal-negative EACs, and inversely correlated with patient overall survival. The M2/M1 ratio was not related to LVD. EAC cell polarised THP1 cell into M2d-like macrophage, which promoted EAC cell migration and invasion. Neoadjuvant therapy appeared to diminish the correlation between the M2/M1 ratio and survival.

Conclusions:: The ratio of M2/M1 macrophage may serve as a sensitive marker to predict lymph node metastasis and poor prognosis in EAC without neoadjuvant therapy. M2d macrophage may have important roles in EAC metastasis.

No MeSH data available.


Related in: MedlinePlus

The associations of the ratio of M2/M1 macrophage with lymph node metastasis and overall survival in EACs with neoadjuvant therapy. (A) The ratio of M2/M1 macrophage is not increased in EAC N1-3 compared with that in EAC N0. (B) Kaplan–Meier overall survival curves of 20 EAC patients stratified by the ratio of M2/M1 macrophage in tumour centre and at tumour edge based on the median number.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4559839&req=5

fig5: The associations of the ratio of M2/M1 macrophage with lymph node metastasis and overall survival in EACs with neoadjuvant therapy. (A) The ratio of M2/M1 macrophage is not increased in EAC N1-3 compared with that in EAC N0. (B) Kaplan–Meier overall survival curves of 20 EAC patients stratified by the ratio of M2/M1 macrophage in tumour centre and at tumour edge based on the median number.

Mentions: Twenty EAC patients with neoadjuvant therapy were included in this study. The data indicated that the counts of M1-like and M2-like macrophage in tumour centre or at tumour edge with and without nodal spread was not statistically different in EACs with neoadjuvant treatment (Supplementary Figure 6). The ratio of M2/M1 macrophage in tumour centre or at tumour edge after neoadjuvant therapy was not associated with lymph node metastasis or OS (Figures 5A and B).


Macrophage subtype predicts lymph node metastasis in oesophageal adenocarcinoma and promotes cancer cell invasion in vitro
The associations of the ratio of M2/M1 macrophage with lymph node metastasis and overall survival in EACs with neoadjuvant therapy. (A) The ratio of M2/M1 macrophage is not increased in EAC N1-3 compared with that in EAC N0. (B) Kaplan–Meier overall survival curves of 20 EAC patients stratified by the ratio of M2/M1 macrophage in tumour centre and at tumour edge based on the median number.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4559839&req=5

fig5: The associations of the ratio of M2/M1 macrophage with lymph node metastasis and overall survival in EACs with neoadjuvant therapy. (A) The ratio of M2/M1 macrophage is not increased in EAC N1-3 compared with that in EAC N0. (B) Kaplan–Meier overall survival curves of 20 EAC patients stratified by the ratio of M2/M1 macrophage in tumour centre and at tumour edge based on the median number.
Mentions: Twenty EAC patients with neoadjuvant therapy were included in this study. The data indicated that the counts of M1-like and M2-like macrophage in tumour centre or at tumour edge with and without nodal spread was not statistically different in EACs with neoadjuvant treatment (Supplementary Figure 6). The ratio of M2/M1 macrophage in tumour centre or at tumour edge after neoadjuvant therapy was not associated with lymph node metastasis or OS (Figures 5A and B).

View Article: PubMed Central - PubMed

ABSTRACT

Background:: Currently, there is a lack of ideal biomarkers for predicting nodal status in preoperative stage of oesophageal adenocarcinoma (EAC) to aid optimising therapeutic options. We studied the potential of applying subtype macrophages to predict lymph node metastasis and prognosis in EAC.

Material and methods:: Fifty-three EAC resection specimens were immunostained with CD68, CD40 (M1), and CD163 (M2). Lymphatic vessel density (LVD) was estimated with the staining of D2-40. Subsequently, we tested if M2d macrophage could promote EAC cell migration and invasion.

Results:: In EAC without neoadjuvant treatment, an increase in M2-like macrophage was associated with poor patient survival, independent of the locations of macrophages in tumour. The M2/M1 ratio that represented the balance between M2- and M1-like macrophages was significantly higher in nodal-positive EACs than that in nodal-negative EACs, and inversely correlated with patient overall survival. The M2/M1 ratio was not related to LVD. EAC cell polarised THP1 cell into M2d-like macrophage, which promoted EAC cell migration and invasion. Neoadjuvant therapy appeared to diminish the correlation between the M2/M1 ratio and survival.

Conclusions:: The ratio of M2/M1 macrophage may serve as a sensitive marker to predict lymph node metastasis and poor prognosis in EAC without neoadjuvant therapy. M2d macrophage may have important roles in EAC metastasis.

No MeSH data available.


Related in: MedlinePlus